The world shares the reflection of liver disease in a new experience
Aaron Sanyal, PhD in Medicine, Director of the VCU Stravitz-Sanyal in liver and metabolic health, discusses the clinical experiment that included 800 participants, as it was a weekly dose of celestial degrees effective in treating fatty liver.
Use Smagedide injectionScientists were able to reflect life -threatening liver disease in a new clinical trial published in the New England magazine.
The poultryide, which is traditionally considered a treatment for type 2 diabetes, was given to the participants who have been diagnosed with life in liver diseases called MASH.
“This is a big step forward in this field,” said Aaron Sanyal, director of the VCU Stravitz-Sanyal in liver and metabolic health. Patients provide additional options when we think about treatment Lipoplasty“
Joe Rogan abandoned drinking alcohol for this simple reason
Hormone is an acute form of democratic liver disease associated with the MALD, which was previously known as non -alcoholic fatty liver disease, according to WebMD.
Hormone is an acute form of worldly liver disease associated with the MALD, which was previously known as non -alcoholic fatty liver. (Istock)
Mash and Masld are characterized by excessive fat in the liver, which can be dangerous.
“Over time, the accumulation of fat in the liver can lead to inflammation and cirrhosis of the liver, cirrhosis and liver cancer,” a press release about the study stated.
The first GLP-1 weight loss pill, and diabetes shows the success of the experiment late in the stage
The researchers chose to investigate the semaglootide as a potential treatment because this group of the drug has previously proven to reduce fat and liver scars for people who suffer from mash.
Between 2021 and 2023, 800 participants who were randomly chosen in 37 countries received injections every week of the imaginary or imaginary medicine. It was more than half Type 2 diabetes About 75 % were obese.
Participants who were treated with Simajlotide had improvements in liver enzymes and other liver measures from cirrhosis, along with weight loss by 10.5 %. (Istock)
After 72 weeks of treatment, 62.9 % of the participants were less than inflammation and fat accumulation in their liver.
In the imaginary drug group, only 34.3 % of the participants witnessed a decrease in symptoms.
“The liver actually starts greatly better under a microscope in these patients,” Sanyal noted.
Ozmpic, other semaglutides associated with hair loss: Here is what to know
The researchers also found that 36.8 % of the semaglutide group witnessed improvements in cirrhosis, compared to 22.4 % in the imaginary drug group.
The participants who were treated with simajlotide also saw improvements in liver enzymes and blood scales from cirrhosis, as well as 10.5 % weight loss.
“I was working with GLP-1 treatments for 16 years and these results are very exciting.”
Some of the negative experiences were more common in the group of semules, including nausea, diarrhea, constipation and vomiting.
“Novo Nordisk continues to explore the gossip via metabolism and Cardiovascular healthAnna Windel, Vice -President of Clinical Development, Medical and Organizational Affairs in Novo Nordisk, Ozmbech and Wugovi maker, said in a press statement submitted to Fox News Digital.
Click here to register in our health newsletter
“We encourage these results published in the Nejm and what this might mean for patients. Based on this data, we look forward to working with the organizational authorities to bring the possible new treatment option for patients.”
“Although these results should be treated with caution, the analysis shows that depressive can be an effective tool for this advanced liver disease,” said the leader of the experiment. (Istock)
“While these results should be treated with caution, the analysis shows that Emma can be the effective tool for this advanced liver disease,” said the main researcher, Professor Philip News, Director of the Roger Williams Institute for Liver Studies at Kings College in London.
Click here to get the Fox News app
“I was working with GLP-1 treatments for 16 years and these results are very exciting,” he added.
Sanyal noticed that the fat in the semules has already been proven to be useful For obesityDiabetes and heart disease.
“Now we can add liver disease to that list.”
For more health articles, visit www.foxnews.com/health
In the future, the research team plans for Collection Of the about 1,200 participants in 37 countries for up to five years to determine the Smaglutide effect on liver complications in the long run.
https://static.foxnews.com/foxnews.com/content/uploads/2023/10/man-stomach-pain.jpg
Source link